5-Amino-1MQ

5-Amino-1MQ was designed as a pharmacological research tool to interrogate NNMT biology in fat cells. It became a community longevity drug before the researchers who designed it published a single human safety study.

Nicotinamide N-methyltransferase (NNMT) was first identified as a metabolic enzyme responsible for the biotransformation and detoxification of nicotinamide and other vitamin B3-related compounds. Under physiological conditions, NNMT is strongly expressed in the liver, where it methylates nicotinamide using SAM as the methyl donor — producing 1-methylnicotinamide (1-MNA) that is then further oxidized and excreted in urine. This was originally understood as a simple catabolic disposal pathway. The implications for NAD+ biology, fat metabolism, and epigenetics came later.

Stanley Watowich's group at the University of Texas Medical Branch, and particularly Hari Neelakantan, developed 5-Amino-1MQ through a systematic medicinal chemistry program aimed at creating selective, cell-permeable NNMT inhibitors for research use. The 2017 Journal of Medicinal Chemistry paper (Neelakantan et al., PMID 29059531) established 5-Amino-1MQ as the reference compound of the class: potent NNMT inhibition; excellent membrane permeability; measurable reduction of intracellular 1-MNA confirming on-target engagement. The compound was designed and intended as a laboratory tool for studying NNMT function in adipocytes and metabolic tissue.

THE CENTRAL TENSION

5-Amino-1MQ raises NAD+ not by adding more of anything, but by stopping the body from throwing nicotinamide away. NNMT converts nicotinamide into a metabolic dead-end (1-MNA) that cannot be used for NAD+ synthesis and is simply excreted. Block NNMT, and nicotinamide is redirected toward NAD+ production instead. SAM — consumed in the process — is also spared, potentially improving global cellular methylation capacity. The mouse data is genuinely impressive: fat loss without food restriction, muscle function improvement in aged animals, NAD+ elevation. The human evidence base is zero. The community uses it at doses extrapolated from mouse IP injection data using allometric scaling that does not account for oral vs IP bioavailability differences. Clinics are prescribing it to humans. The FDA has made no ruling on its safety. A 2025 Cell Press review calls for clinical translation. And the molecule being blocked — 1-MNA — has documented protective roles in liver and kidney biology that the community narrative has largely ignored. This is the most enthusiasm-versus-evidence gap of any compound in this book.

The safety profile of 5-Amino-1MQ in humans is essentially unknown. The preclinical data is reassuring but insufficient. No serious adverse effects were observed in mouse studies, but mice are not humans and IP injection is not oral administration.

Mouse safety data: no significant hepatotoxicity, nephrotoxicity, or hematological changes were reported in the published studies at effective doses. This is the primary safety evidence available. Community experience: at 50-100 mg/day oral, community users report generally good tolerability; occasional reports of insomnia (suggesting some stimulatory effect — consistent with elevated NAD+/sirtuin activity); occasional GI discomfort; liver enzyme monitoring is recommended by community practitioners given the liver is the primary site of NNMT activity and the 1-MNA protective roles are hepatic.

The 1-MNA concern in practice: if NNMT inhibition reduces hepatic 1-MNA production significantly, and 1-MNA has documented hepatoprotective roles (ischemia-reperfusion injury protection; AKT/FOXO1/ANGPT2 axis), then chronic NNMT inhibition could theoretically reduce hepatic resilience to injury. This is a theoretical concern based on the 2025 Nature Communications 1-MNA hepatoprotection finding — not a documented adverse event in any human. It warrants monitoring. Liver enzymes (ALT/AST) should be checked at baseline and 4-8 weeks into use.

The SAM methylation consequence: by blocking NNMT and sparing SAM from nicotinamide methylation, 5-Amino-1MQ theoretically increases SAM availability for other methylation reactions throughout the cell. Whether this globally increases methylation in beneficial or harmful ways — increased DNA methylation in epigenetically important regions, altered histone methylation patterns, changed neurotransmitter methylation — is completely uncharacterized in humans. SAM is the universal methyl donor: anything that substantially changes its availability has the potential for broad downstream effects on the methylome. This is a theoretical concern, not a documented one.

Safety Parameter

Known Status

Monitoring Recommendation

Hepatotoxicity

No signal in mouse studies; 1-MNA depletion theoretically reduces hepatic resilience

ALT/AST at baseline and 4-8 weeks; discontinue if >2x ULN

Renal toxicity

No signal in mice; 1-MNA has anti-fibrotic renal effects in animal data

Creatinine at baseline if pre-existing renal concerns

Insomnia

Community-reported; consistent with elevated NAD+/sirtuin stimulation

Morning-only dosing; never evening

SAM methylation effects

Unknown in humans; theoretical consequence of increased SAM availability

No specific monitoring available; theoretical only

Cancer implications

NNMT overexpression promotes cancer; inhibition is anti-tumorigenic in cancer models

No active malignancy concern identified; contrariwise potentially protective

Drug interactions

NNMT metabolizes some drugs and xenobiotics; inhibition could alter their metabolism

Review concurrent medications with prescriber

To understand what 5-Amino-1MQ does, you need to understand NNMT's place in the nicotinamide metabolic network and why its inhibition is pharmacologically interesting.

The preclinical evidence for 5-Amino-1MQ is genuinely interesting — multiple independent mouse studies showing fat loss, NAD+ elevation, and muscle benefits. The entire evidence base is rodent-derived with IP injection as the route.

The community dose of 50-100 mg/day is the output of a calculation — but the calculation has a methodological problem that is worth understanding before using it.

The mouse studies used intraperitoneal (IP) injection at 10-20 mg/kg. IP injection delivers the compound directly into the peritoneal cavity, where it is absorbed into the portal circulation without first-pass intestinal metabolism. Oral bioavailability for most small molecules is substantially lower than IP bioavailability due to GI degradation and first-pass hepatic metabolism. The allometric scaling from mouse to human uses a conversion factor of approximately 12.3 (dividing by body surface area ratio) to account for metabolic rate differences between species. Applied to the mouse doses: 10-20 mg/kg in mice → divided by 12.3 → approximately 0.8-1.6 mg/kg human equivalent → for a 70 kg person → approximately 56-112 mg. The community landed on 50-100 mg oral as the working dose. The problem: the allometric conversion addresses the species metabolic rate difference but does not address the route difference. If oral bioavailability of 5-Amino-1MQ is 30-50% of IP bioavailability (a reasonable assumption for a quaternary ammonium salt), the actual effective exposure at 100 mg oral may be substantially lower than the mouse IP exposure at the effective mouse dose. No published pharmacokinetic study exists for oral 5-Amino-1MQ in any species to calibrate this.

WHAT THE COMMUNITY DOSE ACTUALLY REPRESENTS

The 50-100 mg/day community dose is not validated human pharmacokinetics. It is allometric scaling from IP mouse data without route-of-administration correction, applied to an oral compound with unknown human oral bioavailability. The dose may be too low to replicate the mouse effects (if oral bioavailability is poor); it may be appropriately dosed; or there is no way to know without human PK data. The absence of published human pharmacokinetics is the foundational knowledge gap for community dosing. Clinics prescribing 5-Amino-1MQ at 50-100 mg/day are operating on the same extrapolated calculation, not on human dose-response data.

Both 5-Amino-1MQ and NMN/NR raise intracellular NAD+. The mechanisms are fundamentally different and potentially synergistic rather than competing. NMN and NR add NAD+ precursors — they increase the supply side of NAD+ synthesis. 5-Amino-1MQ reduces the catabolic drain — it decreases the rate at which nicotinamide is removed from the NAD+ precursor pool. In metabolic disease states where NNMT is overexpressed, the catabolic drain is accelerated — meaning NAD+ precursor supplementation competes directly with an upregulated disposal system. NNMT inhibition addresses the disposal system; NMN/NR address the supply. The theoretical case for combining them: in NNMT-overexpressed obesity, combine NMN (increases precursor flux) with 5-Amino-1MQ (reduces catabolic drain) for greater NAD+ elevation than either alone. This has not been tested in humans. The mouse data for the combination is encouraging from the 2021 Sampson study (where NNMT inhibition + dietary intervention was synergistic for liver fat).

Parameter

5-Amino-1MQ

NMN

NR

Mechanism

NNMT inhibition — prevents nicotinamide catabolism

Precursor supplementation — adds NMN directly

Precursor supplementation — NR converted to NMN

Route

Oral small molecule

Oral (or injectable SubQ)

Oral

Human evidence

Zero trials

Grade B — multiple human RCTs

Grade B — multiple human RCTs

NAD+ elevation

Preclinical: yes (mouse adipose)

Grade B: confirmed in human blood/muscle (Yoshino 2021)

Grade B: confirmed in human blood

Effect in NNMT-overexpressed tissue

Directly addresses the overactive drain

Adds to supply competing with overactive drain

Adds to supply competing with overactive drain

Safety profile

Unknown in humans

Grade B — well-tolerated in human trials

Grade B — well-tolerated in human trials

Cost per month

~$60-80 (research vendor)

~$50-100 (quality NMN)

~$40-80

A 2025 Trends in Pharmacological Sciences review (Cell Press) specifically highlighted emerging opportunities for NNMT inhibitor clinical translation — the first high-profile call from a mainstream pharmacology journal for 5-Amino-1MQ class compounds to enter human clinical trials. The same review noted that clinics had already begun administering NNMT inhibitors to humans without FDA safety rulings. The regulatory status as of mid-2026: 5-Amino-1MQ is not on the FDA 503A bulk drug substances list (the list of compounds that compounding pharmacies can use to make patient-specific compounds). This means there is no legitimate compounding pathway for physician prescription in the US. Clinics prescribing it are operating outside standard regulatory channels. The compound is available as a research chemical from multiple vendors with variable quality.

The clinical translation pathway that has been proposed: Phase 1 human safety and PK study (oral 5-Amino-1MQ, single and multiple ascending doses; measure NNMT inhibition biomarkers — 1-MNA suppression, NAD+ elevation in blood; safety and tolerability); Phase 2 metabolic disease (diet-induced obesity, NAFLD/MASLD — following the mouse Sampson combination data); NNMT as a biomarker: NNMT activity is measurable in urine (1-MNA/creatinine ratio is used as a research biomarker); this provides a translatable PD endpoint for human trials that would allow dose-response characterization in Phase 1.

• What is the oral bioavailability of 5-Amino-1MQ in humans? Without this, the community dose of 50-100 mg/day cannot be calibrated to the effective mouse dose.
• Does oral 5-Amino-1MQ produce measurable NNMT inhibition in human adipose, liver, and muscle tissue at community doses? The 1-MNA/creatinine ratio in urine is a translatable biomarker that could answer this in a Phase 1 trial.
• What are the consequences of chronic NNMT inhibition and 1-MNA depletion in the human liver and kidney? The 2025 Nature Communications hepatoprotection data and the 2022 FASEB renal anti-fibrosis data create specific unanswered questions about the safety of depleting this metabolite long-term.
• Does NNMT inhibition genuinely raise NAD+ in human adipose and muscle tissue as it does in mice? Blood NAD+ elevation from NMN is established; whether NNMT inhibition adds to this or produces comparable elevation from the catabolism-reduction side has not been measured in humans.
• Does 5-Amino-1MQ produce meaningful fat loss in calorie-controlled humans as it does in ad libitum-fed obese mice? The mouse data is impressive; translation requires a human controlled trial.
• Does altering SAM availability through NNMT inhibition have downstream epigenetic consequences — changes in DNA methylation or histone methylation patterns — that are beneficial, harmful, or neutral?

5-Amino-1MQ has an elegant mechanism, compelling mouse data, and zero human trials. The gap between community enthusiasm and evidence is wider here than for almost any other compound in this book.

The mechanism is genuinely interesting — blocking the catabolic drain on nicotinamide is conceptually distinct from and potentially synergistic with NAD+ precursor supplementation. The mouse fat loss data (independent of food restriction) is pharmacologically novel. The muscle aging data adds a second clinically relevant application. The Sampson diet-plus-NNMT-inhibitor synergy for liver fat is the most compelling data point for translational application in NAFLD/MASLD, where the same combination approach could be tested in humans. The 2025 Cell/TPS call for clinical translation represents increasing mainstream recognition of the compound's potential.

The honest assessment of community use: the dose has not been validated in humans; the route extrapolation has a methodological gap; the 1-MNA consequences are not characterized in humans; no safety study has been done in any human; liver enzyme monitoring is the minimum harm reduction measure. Using 5-Amino-1MQ today means being a self-experimenter at the earliest preclinical-to-human translation stage. This is categorically different from using semaglutide (Grade A, thousands of patients, FDA-approved) or even cagrilintide (Phase 3 complete, NEJM publication). It is at the same evidence stage as the earliest research chemicals in this book — with the additional complication that the target (NNMT/1-MNA) has more complex biology than initially appreciated.